REPORT ID 4826

EMEA (Europe, Middle East and Africa) Prophylactic Human Vaccine Market Report 2017

Publish Date
19-Dec-17
Pages
105
Format
Electronic (PDF)

In this report, the EMEA Prophylactic Human Vaccine market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022.

Geographically, this report split EMEA into Europe, the Middle East and Africa, With sales (K Pcs), revenue (Million USD), market share and growth rate of Prophylactic Human Vaccine for these regions, from 2012 to 2022 (forecast)
    Europe: Germany, France, UK, Russia, Italy and Benelux;
    Middle East: Saudi Arabia, Israel, UAE and Iran;
    Africa: South Africa, Nigeria, Egypt and Algeria.

EMEA Prophylactic Human Vaccine market competition by top manufacturers/players, with Prophylactic Human Vaccine sales volume (K Pcs), price (USD/Pcs), revenue (Million USD) and market share for each manufacturer/player; the top players including
    GSK
    Biovac
    McKesson Medical
    Merck
    Merial
    Zoetis
    Sanofi
    ...

On the basis of product, this report displays the sales volume, revenue, product price, market share and growth rate of each type, primarily split into
    Inactivated Vaccine
    Attenuated Vaccine
    Others

On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate for each application, including
    Hospital
    Scientific Research
    Others

If you have any special requirements, please let us know and we will offer you the report as you want.

 
			   
Table of Contents

EMEA (Europe, Middle East and Africa) Prophylactic Human Vaccine Market Report 2017
1 Prophylactic Human Vaccine Overview
    1.1 Product Overview and Scope of Prophylactic Human Vaccine
    1.2 Classification of Prophylactic Human Vaccine
        1.2.1 EMEA Prophylactic Human Vaccine Market Size (Sales) Comparison by Type (2012-2022)
        1.2.2 EMEA Prophylactic Human Vaccine Market Size (Sales) Market Share by Type (Product Category) in 2016
        1.2.3 Inactivated Vaccine
        1.2.4 Attenuated Vaccine
        1.2.5 Others
    1.3 EMEA Prophylactic Human Vaccine Market by Application/End Users
        1.3.1 EMEA Prophylactic Human Vaccine Sales (Volume) and Market Share Comparison by Application (2012-2022
        1.3.2 Hospital
        1.3.3 Scientific Research
        1.3.4 Others
    1.4 EMEA Prophylactic Human Vaccine Market by Region
        1.4.1 EMEA Prophylactic Human Vaccine Market Size (Value) Comparison by Region (2012-2022)
        1.4.2 Europe Status and Prospect (2012-2022)
        1.4.3 Middle East Status and Prospect (2012-2022)
        1.4.4 Africa Status and Prospect (2012-2022)
    1.5 EMEA Market Size (Value and Volume) of Prophylactic Human Vaccine (2012-2022)
        1.5.1 EMEA Prophylactic Human Vaccine Sales and Growth Rate (2012-2022)
        1.5.2 EMEA Prophylactic Human Vaccine Revenue and Growth Rate (2012-2022)

2 EMEA Prophylactic Human Vaccine Competition by Manufacturers/Players/Suppliers, Region, Type and Application
    2.1 EMEA Prophylactic Human Vaccine Market Competition by Players/Manufacturers
        2.1.1 EMEA Prophylactic Human Vaccine Sales Volume and Market Share of Major Players (2012-2017)
        2.1.2 EMEA Prophylactic Human Vaccine Revenue and Share by Players (2012-2017)
        2.1.3 EMEA Prophylactic Human Vaccine Sale Price by Players (2012-2017)
    2.2 EMEA Prophylactic Human Vaccine (Volume and Value) by Type/Product Category
        2.2.1 EMEA Prophylactic Human Vaccine Sales and Market Share by Type (2012-2017)
        2.2.2 EMEA Prophylactic Human Vaccine Revenue and Market Share by Type (2012-2017)
        2.2.3 EMEA Prophylactic Human Vaccine Sale Price by Type (2012-2017)
    2.3 EMEA Prophylactic Human Vaccine (Volume) by Application
    2.4 EMEA Prophylactic Human Vaccine (Volume and Value) by Region
        2.4.1 EMEA Prophylactic Human Vaccine Sales and Market Share by Region (2012-2017)
        2.4.2 EMEA Prophylactic Human Vaccine Revenue and Market Share by Region (2012-2017)
        2.4.3 EMEA Prophylactic Human Vaccine Sales Price by Region (2012-2017)

3 Europe Prophylactic Human Vaccine (Volume, Value and Sales Price), by Players, Countries, Type and Application
    3.1 Europe Prophylactic Human Vaccine Sales and Value (2012-2017)
        3.1.1 Europe Prophylactic Human Vaccine Sales Volume and Growth Rate (2012-2017)
        3.1.2 Europe Prophylactic Human Vaccine Revenue and Growth Rate (2012-2017)
    3.2 Europe Prophylactic Human Vaccine Sales and Market Share by Type
    3.3 Europe Prophylactic Human Vaccine Sales and Market Share by Application
    3.4 Europe Prophylactic Human Vaccine Sales Volume and Value (Revenue) by Countries
        3.4.1 Europe Prophylactic Human Vaccine Sales Volume by Countries (2012-2017)
        3.4.2 Europe Prophylactic Human Vaccine Revenue by Countries (2012-2017)
        3.4.3 Germany Prophylactic Human Vaccine Sales and Growth Rate (2012-2017)
        3.4.4 France Prophylactic Human Vaccine Sales and Growth Rate (2012-2017)
        3.4.5 UK Prophylactic Human Vaccine Sales and Growth Rate (2012-2017)
        3.4.6 Russia Prophylactic Human Vaccine Sales and Growth Rate (2012-2017)
        3.4.7 Italy Prophylactic Human Vaccine Sales and Growth Rate (2012-2017)
        3.4.8 Benelux Prophylactic Human Vaccine Sales and Growth Rate (2012-2017)

4 Middle East Prophylactic Human Vaccine (Volume, Value and Sales Price), by Region, Type and Application
    4.1 Middle East Prophylactic Human Vaccine Sales and Value (2012-2017)
        4.1.1 Middle East Prophylactic Human Vaccine Sales Volume and Growth Rate (2012-2017)
        4.1.2 Middle East Prophylactic Human Vaccine Revenue and Growth Rate (2012-2017)
    4.2 Middle East Prophylactic Human Vaccine Sales and Market Share by Type
    4.3 Middle East Prophylactic Human Vaccine Sales and Market Share by Application
    4.4 Middle East Prophylactic Human Vaccine Sales Volume and Value (Revenue) by Countries
        4.4.1 Middle East Prophylactic Human Vaccine Sales Volume by Countries (2012-2017)
        4.4.2 Middle East Prophylactic Human Vaccine Revenue by Countries (2012-2017)
        4.4.3 Saudi Arabia Prophylactic Human Vaccine Sales and Growth Rate (2012-2017)
        4.4.4 Israel Prophylactic Human Vaccine Sales and Growth Rate (2012-2017)
        4.4.5 UAE Prophylactic Human Vaccine Sales and Growth Rate (2012-2017)
        4.4.6 Iran Prophylactic Human Vaccine Sales and Growth Rate (2012-2017)

5 Africa Prophylactic Human Vaccine (Volume, Value and Sales Price) by Players, Countries, Type and Application
    5.1 Africa Prophylactic Human Vaccine Sales and Value (2012-2017)
        5.1.1 Africa Prophylactic Human Vaccine Sales Volume and Growth Rate (2012-2017)
        5.1.2 Africa Prophylactic Human Vaccine Revenue and Growth Rate (2012-2017)
    5.2 Africa Prophylactic Human Vaccine Sales and Market Share by Type
    5.3 Africa Prophylactic Human Vaccine Sales and Market Share by Application
    5.4 Africa Prophylactic Human Vaccine Sales Volume and Value (Revenue) by Countries
        5.4.1 Africa Prophylactic Human Vaccine Sales Volume by Countries (2012-2017)
        5.4.2 Africa Prophylactic Human Vaccine Revenue by Countries (2012-2017)
        5.4.3 South Africa Prophylactic Human Vaccine Sales and Growth Rate (2012-2017)
        5.4.4 Nigeria Prophylactic Human Vaccine Sales and Growth Rate (2012-2017)
        5.4.5 Egypt Prophylactic Human Vaccine Sales and Growth Rate (2012-2017)
        5.4.6 Algeria Prophylactic Human Vaccine Sales and Growth Rate (2012-2017)

6 EMEA Prophylactic Human Vaccine Manufacturers/Players Profiles and Sales Data
    6.1 GSK
        6.1.1 Company Basic Information, Manufacturing Base and Competitors
        6.1.2 Prophylactic Human Vaccine Product Type, Application and Specification
            6.1.2.1 Product A
            6.1.2.2 Product B
        6.1.3 GSK Prophylactic Human Vaccine Sales, Revenue, Price and Gross Margin (2012-2017)
        6.1.4 Main Business/Business Overview
    6.2 Biovac
        6.2.1 Company Basic Information, Manufacturing Base and Competitors
        6.2.2 Prophylactic Human Vaccine Product Type, Application and Specification
            6.2.2.1 Product A
            6.2.2.2 Product B
        6.2.3 Biovac Prophylactic Human Vaccine Sales, Revenue, Price and Gross Margin (2012-2017)
        6.2.4 Main Business/Business Overview
    6.3 McKesson Medical
        6.3.1 Company Basic Information, Manufacturing Base and Competitors
        6.3.2 Prophylactic Human Vaccine Product Type, Application and Specification
            6.3.2.1 Product A
            6.3.2.2 Product B
        6.3.3 McKesson Medical Prophylactic Human Vaccine Sales, Revenue, Price and Gross Margin (2012-2017)
        6.3.4 Main Business/Business Overview
    6.4 Merck
        6.4.1 Company Basic Information, Manufacturing Base and Competitors
        6.4.2 Prophylactic Human Vaccine Product Type, Application and Specification
            6.4.2.1 Product A
            6.4.2.2 Product B
        6.4.3 Merck Prophylactic Human Vaccine Sales, Revenue, Price and Gross Margin (2012-2017)
        6.4.4 Main Business/Business Overview
    6.5 Merial
        6.5.1 Company Basic Information, Manufacturing Base and Competitors
        6.5.2 Prophylactic Human Vaccine Product Type, Application and Specification
            6.5.2.1 Product A
            6.5.2.2 Product B
        6.5.3 Merial Prophylactic Human Vaccine Sales, Revenue, Price and Gross Margin (2012-2017)
        6.5.4 Main Business/Business Overview
    6.6 Zoetis
        6.6.1 Company Basic Information, Manufacturing Base and Competitors
        6.6.2 Prophylactic Human Vaccine Product Type, Application and Specification
            6.6.2.1 Product A
            6.6.2.2 Product B
        6.6.3 Zoetis Prophylactic Human Vaccine Sales, Revenue, Price and Gross Margin (2012-2017)
        6.6.4 Main Business/Business Overview
    6.7 Sanofi
        6.7.1 Company Basic Information, Manufacturing Base and Competitors
        6.7.2 Prophylactic Human Vaccine Product Type, Application and Specification
            6.7.2.1 Product A
            6.7.2.2 Product B
        6.7.3 Sanofi Prophylactic Human Vaccine Sales, Revenue, Price and Gross Margin (2012-2017)
        6.7.4 Main Business/Business Overview
    ...

7 Prophylactic Human Vaccine Manufacturing Cost Analysis
    7.1 Prophylactic Human Vaccine Key Raw Materials Analysis
        7.1.1 Key Raw Materials
        7.1.2 Price Trend of Key Raw Materials
        7.1.3 Key Suppliers of Raw Materials
        7.1.4 Market Concentration Rate of Raw Materials
    7.2 Proportion of Manufacturing Cost Structure
        7.2.1 Raw Materials
        7.2.2 Labor Cost
        7.2.3 Manufacturing Expenses
    7.3 Manufacturing Process Analysis of Prophylactic Human Vaccine

8 Industrial Chain, Sourcing Strategy and Downstream Buyers
    8.1 Prophylactic Human Vaccine Industrial Chain Analysis
    8.2 Upstream Raw Materials Sourcing
    8.3 Raw Materials Sources of Prophylactic Human Vaccine Major Manufacturers in 2016
    8.4 Downstream Buyers

9 Marketing Strategy Analysis, Distributors/Traders
    9.1 Marketing Channel
        9.1.1 Direct Marketing
        9.1.2 Indirect Marketing
        9.1.3 Marketing Channel Development Trend
    9.2 Market Positioning
        9.2.1 Pricing Strategy
        9.2.2 Brand Strategy
        9.2.3 Target Client
    9.3 Distributors/Traders List

10 Market Effect Factors Analysis
    10.1 Technology Progress/Risk
        10.1.1 Substitutes Threat
        10.1.2 Technology Progress in Related Industry
    10.2 Consumer Needs/Customer Preference Change
    10.3 Economic/Political Environmental Change

11 EMEA Prophylactic Human Vaccine Market Forecast (2017-2022)
    11.1 EMEA Prophylactic Human Vaccine Sales, Revenue and Price Forecast (2017-2022)
        11.1.1 EMEA Prophylactic Human Vaccine Sales and Growth Rate Forecast (2017-2022)
        11.1.2 EMEA Prophylactic Human Vaccine Revenue and Growth Rate Forecast (2017-2022)
        11.1.3 EMEA Prophylactic Human Vaccine Price and Trend Forecast (2017-2022)
    11.2 EMEA Prophylactic Human Vaccine Sales, Revenue and Growth Rate Forecast by Region (2017-2022)
    11.3 Europe Prophylactic Human Vaccine Sales, Revenue and Growth Rate Forecast by Region (2017-2022)
    11.4 Middle Eastt Prophylactic Human Vaccine Sales, Revenue and Growth Rate Forecast by Region (2017-2022)
    11.5 Africa Prophylactic Human Vaccine Sales, Revenue and Growth Rate Forecast by Region (2017-2022)
    11.6 EMEA Prophylactic Human Vaccine Sales Forecast by Type (2017-2022)
    11.7 EMEA Prophylactic Human Vaccine Sales Forecast by Application (2017-2022)

12 Research Findings and Conclusion

13 Appendix
    13.1 Methodology/Research Approach
        13.1.1 Research Programs/Design
        13.1.2 Market Size Estimation
        13.1.3 Market Breakdown and Data Triangulation
    13.2 Data Source
        13.2.1 Secondary Sources
        13.2.2 Primary Sources
    13.3 Disclaimer